August 6, 2020

For Immediate Release

SPARX Group Co., Ltd.
President and Group CEO Shuhei Abe
(TSE1: 8739)

Mirai Creation Fund II Invests in Aillis, a Start-Up Working in AI Medical Devices

—Conducting R&D in AI medical devices and digitizing the skills of doctors using AI—

TOKYO—August 6, 2020—SPARX Group Co., Ltd. (SPARX; TSE1: 8739) today announced that its Mirai Creation Fund II (two) —established in July 2018— has executed an investment (the amount is not disclosed) in Aillis Inc., a firm that develops and manufactures medical devices and innovates machine learning technologies. It aims to digitize the skills of doctors using artificial intelligence (AI). The company will use this round of fundraising to further accelerate its R&D efforts in AI medical devices, to prepare for global expansion, and to recruit outstanding personnel.

Portfolio Company Outline

Since its founding in November 2017, Aillis has been involved in developing AI-based influenza testing methods that provide rapid diagnoses with a high degree of accuracy. In April 2019, it acquired certification as a Type-1 Medical Device Manufacturing and Marketing Business. The firm continues to grow, as evidenced by the massive clinical trial it conducted in winter 2019, gathering data from more than 10,000 patients. Aillis's team consists of medical practitioners that include four doctors; former members of the Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry; experts in medical AI; and alumni from leading medical device manufacturers. With this diverse team of experts, the firm is capable of quickly developing AI medical devices based on a deep understanding of the medical field, technologies (hardware, software, and AI), and regulations. Based on its mission "to realize a society in which all physicians can share and cultivate expert medical skills," the company continues to contribute to the future of medicine.
For more details on the information provided in this press release, visit Aillis's homepage: https://www.aillis.jp/.

Mirai Creation Fund I and Mirai Creation Fund II Summaries

The Mirai Creation Fund I began operations in November 2015 with financing of JPY 13.5 billion from three companies: Toyota Motor Corporation, Sumitomo Mitsui Banking Corporation, and SPARX, the Fund's general partner. Ultimately, the Fund received contributions from 20 companies, including the above three. Casting intelligent technologies, robotics, and hydrogen-economy technologies as core technologies of the future, Fund I has invested in approximately 50 companies and projects—from the US, the UK, Israel, Singapore, and Japan—that possess innovative technologies in these fields. In H2 2018, SPARX began managing the Mirai Creation Fund II, which targets the three existing Mirai Creation fields along with the two additional areas of electrification and new materials. As of July 31, 2020, the combined AUM for Fund I and Fund II were JPY 109.3 billion.
Mirai Creation Fund investment track record: https://mirai.sparx.co.jp/en/investment/

■ For inquiries related to this release, contact:
Public Relations, SPARX Group Co., Ltd.
Tel: +81-3-6711-9100 / Fax: +81-3-6711-9101
pr_media@sparxgroup.com